ERBB2 and metastatic neoplasm: Given the discordant HER2 results between the breast primary and the metastatic disease, she was referred for 89Zr-ss-pertuzumab PET/CT to help select a liver lesion for biopsy to maximize the chances of HER2-positive disease and subsequent HER2-targeted therapy.